BIOLIFE SOLUTIONS INC — Form 8-K
Filed July 22, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
Repligen Corporation agreed to acquire BioLife Solutions Inc. in an all-stock and cash transaction dated July 21, 2026. BioLife shareholders will receive 0.1442 shares of Repligen common stock plus $11.25 cash per share. The transaction values BioLife at approximately $845M (company's public market value). Both boards unanimously approved; deal is structured as a tax-free reorganization under Section 368(a) of the Internal Revenue Code and subject to BioLife shareholder approval and regulatory clearances including HSR Act compliance.
Why this rating
Transformational M&A at ~100% of target's market cap; materially alters trajectory for both acquirer and target; substantial stock issuance (~19.9% of Repligen shares); reshapes combined company fundamentals and operations.
See more from July 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.